DBV Stock (NASDAQ:DBVT)


RevenueOwnershipFinancialsChartTranscripts

Previous Close

$3.19

52W Range

$0.44 - $4.50

50D Avg

$1.60

200D Avg

$1.20

Market Cap

$67.58M

Avg Vol (3M)

$793.83K

Beta

0.86

Div Yield

-

DBVT Company Profile


DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Yes

Country

FR

Employees

108

IPO Date

Oct 22, 2014

Website

DBVT Performance


DBVT Financial Summary


Dec 23Dec 22Dec 21
Revenue-$4.80M$5.71M
Operating Income$15.73M$-96.63M$-98.61M
Net Income$-72.73M$-96.30M$-97.81M
EBITDA$15.73M$-96.60M$-100.45M
Basic EPS$-0.76$-1.24$-1.78
Diluted EPS$-0.76$-1.24$-1.78

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Jul 30, 24 | 10:03 PM
Q4 23Mar 07, 24 | 9:58 PM
Q3 23Oct 31, 23 | 9:57 PM

Peer Comparison


TickerCompany
CNTACentessa Pharmaceuticals plc
NUVLNuvalent, Inc.
ORICORIC Pharmaceuticals, Inc.
IKNAIkena Oncology, Inc.
EWTXEdgewise Therapeutics, Inc.
INBXInhibrx Biosciences, Inc.
IPHAInnate Pharma S.A.
HCWBHCW Biologics Inc.
MNOVMediciNova, Inc.
ITOSiTeos Therapeutics, Inc.
TARSTarsus Pharmaceuticals, Inc.
RZLTRezolute, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
GNFTGenfit S.A.
EPIXESSA Pharma Inc.
MOLNMolecular Partners AG
LYRALyra Therapeutics, Inc.
CELCCelcuity Inc.
OPTOpthea Limited